EARNING RECAP

Exelixis Inc

#EXEL 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 37c est. 24c $228.6M est. $188.76M +1.71% ($22.05 closing price) $23.59 $21.37 Dec. 31 '18 cash equivalent $851.6M
Q3 41c est. 19c $225.4M est. $172.59M +16.45% ($17.41 closing) $19.20 $16.83 sees FY18 OPEX $410M-$420M
Q2 28c est. 16c $186.1M est. $155.89M +9.16% ($22.40 closing) $23.19 $20.92 maintains FY18 cost estimate of $430M-$460M
Q1 $0.37c Vs 16c $212.3M vs $146.4M +7.76% ($22.22 closing) $23.76 $21.39 collaboration with Invera.
#EXEL 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 12c vs 12c $120.1M vs $120.25M -8.20% ($27.11 closing) $28.63 $27.01 Continue to make progress in sNDA for cabozantinib
Q3 26c vs 8c $152.5M Vs $104.89M +5.32% ($25.52 closing) $26.68 $25.24 The company's top priority remains the ongoing commercialization of Cabometyx tablets as treatments for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
Q2 $0.08 Vs $0.03 Cabozantinib Franchise net product revenue of $88.00M. Total Revenue of $99.0M -3.45% ($25.71 closing) $27.38 $25.41 Net income of $17.7M
Q1 5c Vs 1c Product revenue $68.90m vs $65.23m. Total $80.89m +0.02% ($23.16 closing) $24.85 $22.77 +4.10% @ $24.10 AH. Ph. 3 cabozantinib combination trial in RCC start later this. On track sNDA Q3

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.